Singapore, Singapore

Wei Shiong Adrian Ho

This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignee: Hoffmann-La Roche Inc.. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Shiong Adrian Ho. Retrieved from https://idiyas.com/inventor/wei-shiong-adrian-ho

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Wei Shiong Adrian Ho

Introduction

Wei Shiong Adrian Ho is a notable inventor based in Singapore, SG. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions. With a total of 2 patents to his name, his work focuses on addressing critical health challenges.

Latest Patents

Wei Shiong Adrian Ho's latest patents include bispecific anti-CCL2 antibodies. These antibodies are designed to bind to two different epitopes on human CCL2. The invention encompasses pharmaceutical compositions, their manufacture, and their use as medicaments for the treatment of cancers, inflammatory, autoimmune, and ophthalmologic diseases.

Career Highlights

He is currently associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work at the company emphasizes the importance of innovative solutions in the medical field. His contributions have the potential to impact various therapeutic areas significantly.

Collaborations

Some of his notable coworkers include Jens Fischer and Guy Georges. Their collaboration enhances the research and development efforts within their projects.

Conclusion

Wei Shiong Adrian Ho's innovative work in the field of biotechnology exemplifies the impact of dedicated inventors on healthcare advancements. His patents reflect a commitment to developing effective treatments for complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…